Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lab-Grown tumor models could personalize mesothelioma care

NCT ID NCT07330271

Disease control Sponsor: Beijing Tsinghua Chang Gung Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new way to choose cancer treatments for people with peritoneal mesothelioma. After surgery, doctors will grow a model of the patient's tumor in the lab and test different drugs on it to find the best match. The goal is to see if this personalized approach helps patients live longer without their cancer growing, compared to standard chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 347 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Nov 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients must meet ALL of the following criteria to be eligible for the study: * Aged 18 years or older. * Histopathologically confirmed diagnosis of epithelioid or biphasic malignant peritoneal mesothelioma (MPM). * Scheduled to undergo cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) and subsequent adjuvant therapy. * Availability of sufficient fresh tumor tissue sample obtained during surgery for Patient-derived tumor-like cell clusters (PTC) drug sensitivity testing. * Karnofsky Performance Status (KPS) score \> 60. * Adequate hematologic function: * White blood cell count ≥ 3.5 × 10⁹/L * Platelet count ≥ 80 × 10⁹/L * Adequate hepatic function: * Total bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) \< 2 × upper limit of normal (ULN) * Adequate renal function: * Serum creatinine \< 1.2 × ULN * Adequate cardiac and pulmonary function to tolerate major surgery, as assessed by the investigator. * Voluntarily agrees to participate by providing written informed consent and demonstrates good compliance. Exclusion Criteria: Patients who meet ANY of the following criteria will be excluded from the study: * Presence of concurrent severe medical comorbidities that, in the investigator's judgment, preclude tolerance to the study treatment. * Diagnosis of another active malignant tumor during the screening process, which may interfere with the study outcomes. * Considered by the investigator to be unsuitable for participation in this study for any other reason (e.g., psychological, familial, or social factors). * Unwillingness to accept the assigned treatment regimen or the required follow-up schedule.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Malignant peritoneal mesothelioma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

malignant peritoneal mesothelioma peritoneal mesothelioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Peritoneal mesothelioma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Tsinghua University affiliated Beijing Tsinghua Changgung Hospital

    RECRUITING

    Beijing, 102218, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.